Skip to content
Clinical Trials – home
Fundacion GECP
Sponsor

Fundacion GECP

Spain Avinguda Meridiana 358 6 Planta, 08027 Barcelona, Spain

About the sponsor

Research activity centers on non-small cell lung cancer (NSCLC), including unresectable, resectable, and completely resected disease, with attention to locally advanced and thoracic-confined tumors. The portfolio also includes ALK-positive and KRAS p.G12C disease, as well as upper-lobe and Pancoast presentations.

  • Resectable and unresectable NSCLC
  • ALK-positive lung cancer
  • KRAS p.G12C-mutated NSCLC
  • Thoracic-confined and completely resected disease

Clinical interests include perioperative, adjuvant, and maintenance therapy settings, with outcomes focused on progression-free survival, disease-free survival, and pathological complete response.

About Specializations

Fundacion GECP runs clinical trials in conditions such as Non-small cell lung cancer, Small cell lung cancer limited stage, Non-small cell lung cancer stage IV, Small cell lung cancer extensive stage, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

14 clinical trials

Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tarlatamab
  • Sponsor:Fundacion GECP
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fundacion GECP
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fundacion GECP
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion GECP
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:Fundacion GECP
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Brigatinib
  • Sponsor:Fundacion GECP
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Fundacion GECP
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Fundacion GECP
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Fundacion GECP
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Fundacion GECP
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Fundacion GECP
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Fundacion GECP

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).